GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » ROE %

Opiant Pharmaceuticals (Opiant Pharmaceuticals) ROE % : -158.36% (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Opiant Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2022 was $-39.67 Mil. Opiant Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $25.05 Mil. Therefore, Opiant Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2022 was -158.36%.

The historical rank and industry rank for Opiant Pharmaceuticals's ROE % or its related term are showing as below:

OPNT' s ROE % Range Over the Past 10 Years
Min: -200.02   Med: 7.31   Max: Negative Equity
Current: -92.84

During the past 13 years, Opiant Pharmaceuticals's highest ROE % was Negative Equity%. The lowest was -200.02%. And the median was 7.31%.

OPNT's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.08 vs OPNT: -92.84

Opiant Pharmaceuticals ROE % Historical Data

The historical data trend for Opiant Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals ROE % Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity -200.02 45.22 -5.32 7.31

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.88 6.77 -113.24 -136.36 -158.36

Competitive Comparison of Opiant Pharmaceuticals's ROE %

For the Biotechnology subindustry, Opiant Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's ROE % falls into.



Opiant Pharmaceuticals ROE % Calculation

Opiant Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=3.009/( (35.492+46.84)/ 2 )
=3.009/41.166
=7.31 %

Opiant Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %=Net Income (Q: Sep. 2022 )/( (Total Stockholders Equity (Q: Jun. 2022 )+Total Stockholders Equity (Q: Sep. 2022 ))/ count )
=-39.668/( (29.596+20.502)/ 2 )
=-39.668/25.049
=-158.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.


Opiant Pharmaceuticals  (NAS:OPNT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-39.668/25.049
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-39.668 / 0)*(0 / 45.387)*(45.387 / 25.049)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.8119
=ROA %*Equity Multiplier
=N/A %*1.8119
=-158.36 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-39.668/25.049
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-39.668 / -39.632) * (-39.632 / -38.52) * (-38.52 / 0) * (0 / 45.387) * (45.387 / 25.049)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0009 * 1.0289 * N/A % * 0 * 1.8119
=-158.36 %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Opiant Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
David D O'toole officer: Chief Financial Officer 1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman other: General Counsel 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth officer: Chief Commercial Officer 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair director, 10 percent owner, officer: Executive Chairman 86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson other: General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Headlines